Posted in | News

Lemminkäinen Sells its Building Construction Business in Sweden

Lemminkäinen has completed the sale of its building construction business in Sweden. Lemminkäinen agreed on 5 June 2015 to sell all outstanding shares in its Swedish subsidiary Rekab Entreprenad AB to Rekab’s current management as well as Rekab’s Malmö business to Swedish Wästbygg Group and Rekab’s Uppsala business to Norwegian Veidekke Group.

The competition authorities have approved the sales of the businesses in Uppsala and Malmö. Lemminkäinen and the buyers have agreed not to disclose the transaction prices. The sale has a small negative impact on Lemminkäinen’s result, which the company recorded to the second quarter result. Rekab’s business was transferred from Lemminkäinen as of 1 September 2015.

After the transactions, Lemminkäinen withdraws from the building construction business in Sweden. Rekab’s business in Luleå will be incorporated into Lemminkäinen’s Infra projects business segment.

Lemminkäinen announced the divestment of its building construction business in Sweden on 5 June 2015.

DISTRIBUTION: NASDAQ OMX Helsinki Key media www.lemminkainen.com

Together with our customers we create conditions that make living, working and travelling functional, safe and healthy. We operate in Northern Europe and employ about 5,600 professionals. In 2014, our net sales were about EUR 2.0 billion. Lemminkäinen Corporation's share is quoted on NASDAQ OMX Nordic Exchange Helsinki. www.lemminkainen.com

This information was brought to you by Cision http://news.cision.com

Source: http://www.lemminkainen.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.